2020
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Sundar R, Smyth E, Peng S, Yeong J, Tan P. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Frontiers In Oncology 2020, 10: 763. PMID: 32500029, PMCID: PMC7243739, DOI: 10.3389/fonc.2020.00763.Peer-Reviewed Educational MaterialsImmune checkpoint inhibitionGastroesophageal cancerPredictive biomarkersCheckpoint inhibitionRandomized phase III studyImmune checkpoint inhibitor trialsValidation of predictive biomarkersCheckpoint inhibitor trialsPhase III studySubgroup of patientsIII studiesSurvival benefitInhibitor trialsPatient selectionGastroesophagealNovel biomarkersPrecision oncologyCancer treatmentCancerRegulatory approvalImmunotherapyNegative resultsBiomarkersPatientsInhibition
2016
Emerging biomarkers for PD-1 pathway cancer therapy
Lim J, Sundar R, Chnard-Poirier M, Lopez J, Yap T. Emerging biomarkers for PD-1 pathway cancer therapy. Biomarkers In Medicine 2016, 11: 53-67. PMID: 27936870, DOI: 10.2217/bmm-2016-0228.Peer-Reviewed Educational MaterialsConceptsPD-L1Predictive biomarkers of responseImmune checkpoint inhibitorsImmune-related toxicitiesPD-L1 expressionPD-L1 inhibitorsBiomarkers of responseTreatment response biomarkersMultiple tumor typesIntermediate end pointsCheckpoint inhibitorsPD-1Predictive biomarkersImmuno-oncologyResponse assessmentTumor typesResponse biomarkersCancer therapyEnd pointsTherapy designBiomarkersFDA registrationTreatmentInhibitorsDifferential responding